Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YBEES
ADC Name	Anti-TNF ADC 120
Synonyms	Anti-TNF-ADC-120 Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Rheumatoid arthritis [ICD11:FA20] Investigative
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	Anti-TNF mAb alpha-TNF		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)		Antigen Info
Payload Name	GRM cpd 5		Payload Info
Therapeutic Target	Glucocorticoid receptor (NR3C1)		Target Info
Linker Name	MP-Ala-Ala		Linker Info
Conjugate Type	The free sulfhydryl group obtained by the reduction of interchain cysteine is site-specific conjugated with maleimide, michael addition reaction, followed by incubation at basic ph to hydrolyze-open the maleimide ring.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	0.03	ug/mL	K-562 cells (TNF expression)	Chronic myelogenous leukemia
Half Maximal Effective Concentration (EC50)	8.5	ug/mL	K-562 cells	Chronic myelogenous leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ug/mL	Positive TNF expression (TNF+++/++)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells (TNF expression)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8.50 ug/mL	Negative TNF expression (TNF-)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

References

Ref 1	Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem. 2022 Dec 8;65(23):15893-15934.